Insights from modeling the 3D structure of New Delhi metallo-β-lactamse and its binding interactions with antibiotic drugs

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Wang, Jing Fang ^a,b,c   Chou, Kuo Chen ^c  

^a Shanghai Jiao Tong University   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^c GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BETA LACTAM ANTIBIOTIC; GLUTAMIC ACID; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; NEW DELHI METALLO BETA LACTAMASE; THREONINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE NDM 1; BETA-LACTAMASE NDM-1;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG HYDROLYSIS; DRUG INACTIVATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME STRUCTURE; MODEL; MOLECULAR DOCKING; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; STRUCTURE MODEL; THREE DIMENSIONAL IMAGING; AMINO ACID SEQUENCE; BINDING SITE; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; HYDROGEN BOND; METABOLISM; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; STRUCTURAL HOMOLOGY;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BINDING SITES; BIOCATALYSIS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 79954533005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018414     Document Type: Article

References (58)

1. Giamarellou H, Poulakou G, (2009) Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69: 1879-1901.
2. Livermore DM, (2009) beta-Lactamases- the Threat Renews. Curr Protein Pept Sci 10: 397-400.
3. Maltezou HC, (2009) Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 33: e401-407.
4. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, et al. (2009) Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53: 5046-5054.
5. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P, (2010) Emergence of metallo-ss-lactamase NDM-1-producing multidrug resistant Escherichia coli in Australia. Antimicrob Agents Chemother.
6. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10: 597-602.
7. Chou KC, (2004) Review: Structural bioinformatics and its impact to biomedical science. Current Medicinal Chemistry 11: 2105-2134.
8. Wang JF, Wei DQ, Li L, Zheng SY, Li YX, et al. (2007) 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun 355: 513-519 Erratum in: Biochem Biophys Res Commun 2007, 357: 339; Biochem Biophys Res Commun 2009, 384: 399.
9. Chou KC, (2004) Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5. Biochemical and Biophysical Research Communications 316: 636-642.
10. Wang JF, Wei DQ, Lin Y, Wang YH, Du HL, et al. (2007) Insights from modeling the 3D structure of NAD(P)H-dependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP. Biochem Biophys Res Commun 359: 323-329.
11. Chou KC, (2004) Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochemical and Biophysical Research Communication 319: 433-438.
12. Wang JF, Wei DQ, Chen C, Li Y, Chou KC, (2008) Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept Lett 15: 27-32.
13. Chou KC, (2004) Molecular therapeutic target for type-2 diabetes. Journal of Proteome Research 3: 1284-1288.
14. Wang JF, Wei DQ, Chou KC, (2008) Pharmacogenomics and personalized use of drugs. Curr Top Med Chem 8: 1573-1579.
15. Chou KC, (2005) Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. Journal of Proteome Research 4: 1681-1686.
16. Wang JF, Chou KC, (2009) Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun 390: 608-612.
17. Gong K, Li L, Wang JF, Cheng F, Wei DQ, et al. (2009) Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design. Med Chem 5: 242-249.
18. Gu RX, Gu H, Xie ZY, Wang JF, Arias HR, et al. (2009) Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with alpha7 nicotinic acetylcholine receptor. Med Chem 5: 250-262.
19. Chou KC, Wei DQ, Zhong WZ, (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Comm 308: 148-151.
20. Wang JF, Gong K, Wei DQ, Li YX, Chou KC, (2009) Molecular dynamics studies on the interactions of PTP1B with inhibitors: from the first phosphate-binding site to the second one. Protein Eng Des Sel 22: 349-355.
21. Zeng QK, Du HL, Wang JF, Wei DQ, Wang XN, et al. (2009) Reversal of coenzyme specificity and improvement of catalytic efficiency of Pichia stipitis xylose reductase by rational site-directed mutagenesis. Biotechnol Lett 31: 1025-1029.
22. Wang JF, Chou KC, (2010) Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab 11: 342-346.
23. Li L, Wei DQ, Wang JF, Chou KC, (2007) Computational studies of the binding mechanism of calmodulin with chrysin. Biochem Biophys Res Commun 358: 1102-1107.
24. Wang JF, Yan JY, Wei DQ, Chou KC, (2009) Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem 5: 263-270.
25. Wang JF, Wei DQ, (2009) Role of structural bioinformatics and traditional Chinese medicine databases in pharmacogenomics. Pharmacogenomics 10: 1213-1215.
26. Wang JF, Zhang CC, Chou KC, Wei DQ, (2009) Structure of cytochrome p450s and personalized drug. Curr Med Chem 16: 232-244.
27. Gui H, Chen HF, Wei DQ, Wang JF, (2010) Molecular dynamics simulations exploring drug resistance in HIV-1 proteases. Chinese Sci Bull 55: 2677-2683.
28. Tang B, Gong K, Wang JF, Li YX, Wei DQ, (2010) The structure of phospholamban and its MD simulations. Chinese Sci Bull 55: 1619-1624.
29. Wang JF, Gong K, Wei DQ, Li YX, (2009) Structural flexibility and interactions of PTP1B's S-loop. Interdiscip Sci 1: 214-219.
30. Wang JF, Chou KC, (2010) Insight from studying the mutation-induced allostery in the M2 proton channel by molecular dynamics. Protein Eng Des Sel 23: 663-666.
31. Wang Y, Wei DQ, Wang JF, (2010) Molecular dynamics studies on T1 lipase: insights into a double-flap mechanism. J Chem Inf Model 50: 875-878.
32. Wang JF, Wei DQ, Du HL, Li YX, Chou KC, (2008) Molecular modeling studies on NADP-dependence of candida tropicalis strain xylose reductase. Open Bioinformatics J 2: 72-79.
33. Huang RB, Du QS, Wang CH, Chou KC, (2008) An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem Biophys Res Comm 377: 1243-1247.
34. Du QS, Huang RB, Wang CH, Li XM, Chou KC, (2009) Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus. Journal of Theoretical Biology 259: 159-164.
35. Wei H, Wang CH, Du QS, Meng J, Chou KC, (2009) Investigation into adamantane-based M2 inhibitors with FB-QSAR. Medicinal Chemistry 5: 305-317.
36. Wang JF, Wei DQ, Chou KC, (2009) Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus. Biochem Biophys Res Commun 388: 413-417.
37. Guo X, Wang JF, Zhu Y, Wei DQ, (2010) Recent Progress on Computer-Aided Inhibitor Design of H5N1 Influenza A Virus. Curr Comput Aided Drug Des 6: 139-146.
38. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ, (2006) Review: Progress in computational approach to drug development against SARS. Current Medicinal Chemistry 13: 3263-3270.
39. Du QS, Huang RB, Wang SQ, Chou KC, (2010) Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS ONE 5: e9388.
40. Garcia-Saez I, Docquier JD, Rossolini GM, Dideberg O, (2008) The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. J Mol Biol 375: 604-611.
41. Shen HB, Chou KC, (2007) EzyPred: A top-down approach for predicting enzyme functional classes and subclasses. Biochem Biophys Res Comm 364: 53-59.
42. Zhang Y, (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9: 40.
43. Zhang Y, (2007) Template-based modeling and free modeling by I-TASSER in CASP7. Proteins 69 (Suppl 8): 108-117.
44. Wu S, Skolnick J, Zhang Y, (2007) Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol 5: 17.
45. Chou KC, Carlacci L, (1991) Simulated annealing approach to the study of protein structures. Protein Engineering 4: 661-667.
46. Laurie AT, Jackson RM, (2005) Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21: 1908-1916.
47. Concha NO, Janson CA, Rowling P, Pearson S, Cheever CA, et al. (2000) Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry 39: 4288-4298.
48. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated dokcing using a lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998 19: 1639-1662 Journal of Computational Chemistry 19: 1639-1662.
49. Colotta V, Capelli F, Lenzi O, Catarzi D, Varano F, et al. (2009) Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies. Bioorg Med Chem 17: 401-410.
50. Ricchiuto P, Rocco AG, Gianazza E, Corrada D, Beringhelli T, et al. (2008) Structural and dynamic roles of permanent water molecules in ligand molecular recognition by chicken liver bile acid binding protein. J Mol Recognit 21: 348-354.
51. Magdziarz T, Mazur P, Polanski J, (2009) Receptor independent and receptor dependent CoMSA modeling with IVE-PLS: application to CBG benchmark steroids and reductase activators. J Mol Model 15: 41-51.
52. Laskowski RA, MacArthur MW, Moss D, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283-291.
53. Benkert P, Tosatto SCE, Schomburg D, (2008) QMEAN: A comprehensive scoring function for model quality assessment. Proteins 71: 261-277.
54. Chou KC, Zhang CT, (1995) Review: Prediction of protein structural classes. Critical Reviews in Biochemistry and Molecular Biology 30: 275-349.
55. Chou KC, Watenpaugh KD, Heinrikson RL, (1999) A Model of the complex between cyclin-dependent kinase 5 (Cdk5) and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun 259: 420-428.
56. Wang Z, Fast W, Valentine AM, Benkovic SJ, (1999) Metallo-beta-lactamase: structure and mechanism. Curr Opin Chem Biol 3: 614-622.
57. Xu D, Guo H, Cui Q, (2007) Antibiotic deactivation by a dizinc beta-lactamase: mechanistic insights from QM/MM and DFT studies. J Am Chem Soc 129: 10814-10822.
58. Tamilselvi A, Nethaji M, Mugesh G, (2006) Antibiotic resistance: mono- and dinuclear zinc complexes as metallo-beta-lactamase mimics. Chemistry 12: 7797-7806.